Abstract: Evaluation of VLP-1 levels in combination with at least one of amyloid-? peptide (A?), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.

Abstract: A method for aiding in the determination of whether a living or deceased human is afflicted with or will likely have atherosclerosis respectfully, the method comprising determining the level of SPRR3 protein in a intimae or body fluid sample by using molecular localization analysis technique comparing the determined level of SPRR3 protein in the biological sample obtained from said individual with a range of SPRR3 levels previously defined as characteristic for humans having atherosclerosis, concluding from the comparison that the person is likely suffering from atherosclerosis when a SPRR3 level is in the range previously defined as characteristic for the presence of atherosclerosis as an indication that the individual is suffering from or has suffered from atherosclerosis.

Abstract: A method of determining CK-MB isoenzyme in a biological fluid is disclosed which comprises subjecting a sample of said fluid to an assay system which includes incubating with monoclonal antibody specific to CK-MB isoenzyme, but not reactive with CK-MM or CK-BB. Methods for preparing antibodies with these characteristics and cell lines producing them are also disclosed.